FindTrial
Sign In

Phase III clinical study of MN-10-T AI for patients with osteoporosis at higher fracture risk

Phase III clinical study of MN-10-T AI for patients with osteoporosis at higher fracture risk

Status
Unknown
Phases
Phase 3
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT2080223422
Enrollment
Unknown
Registered
2016-12-22
Start date
2016-12-22
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with osteoporosis at higher fracture risk

Interventions

investigational material(s) Generic name etc : MN-10-T AI INN of investigational material : Teriparatide Therapeutic category code : 399 Agents affecting metabolism, n.e.c. Dosage and Administration f

Sponsors

ASAHI KASEI PHARMA CORPORATION
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Patients with osteoporosis at higher fracture risk

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Percent change in lumbar spine bone mineral density—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026